Free-text search
Articles per year:
Content Types
-
Anocca doses first Swedish patient with its TCR-T therapy
Five patients have so far been treated with Anocca’s in-house developed TCR-T cell therapy candidate for pancreatic cancer, with the latest becoming the first patient in Sweden. The Södertälje-based company is also reporting early signs of biological activity in the Phase I trial.
-
New heart valve can expand as children grow
The US Food and Drug Administration (FDA) has approved a surgically implanted heart valve for children with a special feature: it can be expanded as the child grows.
-
Danish diabetes firm secures MDR approval: “It's not something that you just do”
After formerly obtaining a regulatory for patients over 18 years old, Hedia can now expand its support to pediatric care.
-
Phase III goals met – yet Zealand shares fall
Despite meeting both primary endpoints in a Phase 3 trial of the obesity drug survodutide, Zealand Pharma’s shares fell sharply on Thursday.
-
Sanofi strikes another multibillion-dollar deal – four candidates in focus
Sanofi and Regeneron are stepping up their long-standing partnership. The companies are now investing in four new antibody drugs in a deal that could be worth up to $8 billion.
-
Novo slashes Wegovy price in Sweden – “It makes sense”
Novo is cutting the price of its weight-loss drug Wegovy by 20 per cent in Sweden. According to the company, the move is not aimed at gaining market share, but at reducing the financial burden on patients and making treatment available to more people.
-
€67.5m financing for Danish eyecare candidate
Danish retinal disease treatment company Breye Therapeutics has raised €67.5 million in a Series A financing round.
-
Study finds key gut bacterium undetectable in one in three Swedish infants
One in three Swedish infants have no detectable levels of a bacterium that helps support the developing immune system, according to a new Swedish study. The figure is notably high compared with similar studies from the UK and US.
-
Swedish obesity challenger halts drug programme
Swedish biotech company Empros Pharma is discontinuing its obesity drug programme. Difficulties in securing funding and growing competition from GLP-1 drugs are cited as the reasons.
-
Danish biosolutions company expands U.S. factory
Novonesis has expanded its facility in the U.S. cheese capital.
-
Invisible hearing implant launched – entire device sits beneath the skin
A cochlear implant in which all components, including the microphone, are implanted beneath the skin is now being launched across Europe. According to Ingeborg Hochmair, CEO and co-founder of MED-EL, the idea has been nearly 50 years in the making.
-
Swedish biotech AnaCardio raises €62.5m to advance heart failure drug
Swedish biotech company AnaCardio has raised €62.5 million, equivalent to more than SEK 700 million, in its largest funding round to date. “It’s a big day for us,” says Patrik Strömberg, the company’s CEO.
-
Novo's Wegovy pill is being launched in Denmark – but not by themselves
Novo's Wegovy tablet is coming to its home country soon. But it's not being released by the Danish firm.
-
Anna Törner: Time for new body ideals?
Why are perfectly healthy people turning to high-tech medicines to achieve outdated beauty ideals? Anna Törner asks in her latest column.
-
Kodiak shares more than double after positive eye drug results
A successful Phase III trial in age-related macular degeneration sent shares in US-based Kodiak Sciences soaring on Monday.
-
Phase III results approach for Cinclus – “We are hopeful”
Cinclus Pharma, which is developing new therapies for acid-related diseases, has now completed all planned patient visits in an ongoing Phase III trial. Preliminary topline results are expected later this year.
-
Novo Nordisk licenses weight-loss pill in deal worth up to 2.6 billion dollars
Novo Nordisk has entered into an exclusive licensing agreement with Chinese pharmaceutical company Hengrui Pharma for HRS-1596, an oral GLP-1/GIP dual agonist with the potential for once-weekly dosing.
-
Merck expands cancer pipeline with KRAS deal
Merck & Co has signed a licensing agreement worth up to $2.13 billion for global rights to a preclinical cancer drug candidate from Chinese biotech company SciBrunch Therapeutics.
-
Egetis lands FDA approval: “Biggest milestone in the company’s history”
Swedish Egetis Therapeutics has secured FDA approval for its rare disease drug Emcitate, clearing the way for a US launch within weeks. “We are transitioning from a late-stage development biotech company into a commercial company,” CEO Nicklas Westerholm tells Life Science Focus.
-
AstraZeneca bets $2bn on Summit’s cancer drug
AstraZeneca is investing 2 billion dollars in US-based Summit Therapeutics to accelerate the development of the cancer drug ivonescimab in combination with antibody-drug conjugates, or ADCs.
-
Elekta shows promising results in pancreatic cancer
Patients had localised pancreatic cancer but were not eligible for surgery. Following high-dose, MRI-guided radiotherapy with Elekta Unity, around 26 per cent were alive after three years, according to a new study.
-
Biontech to close three factories in Germany – 1,800 employees affected
German pharmaceutical company Biontech will close its facilities in Tübingen, Marburg and Idar-Oberstein after failing to find buyers. Around 1,800 employees are affected, Bild reports.
-
Swedish Alzheimer’s project wins 19 million dollar US research grant
An Alzheimer’s research project led by associate professor Sebastian Palmqvist at Lund University has been awarded 19.4 million dollars in US research funding. The aim is to develop a new FDA-approved blood test for the disease within five years.
-
AbbVie wins FDA approval for new Parkinson’s treatment
A new drug for Parkinson’s disease has been approved in the US
BREAKING